You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 19, 2025

Drug Price Trends for NDC 51167-0700


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 51167-0700

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
ORKAMBI (LUMACAFTOR/IVACAFTOR) 100MG/125MG Vertex Pharmaceuticals, Inc. 51167-0700-02 112 17749.15 158.47455 2024-05-01 - 2029-04-30 Big4
ORKAMBI (LUMACAFTOR/IVACAFTOR) 100MG/125MG Vertex Pharmaceuticals, Inc. 51167-0700-02 112 22054.54 196.91554 2024-05-01 - 2029-04-30 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 51167-0700

Last updated: July 27, 2025

Introduction

The drug with National Drug Code (NDC) 51167-0700 is a specialized pharmaceutical product whose market dynamics and pricing are critical for stakeholders—including manufacturers, healthcare providers, insurers, and investors. Accurate market analysis encompasses assessment of regulatory status, therapeutic landscape, competitive positioning, manufacturing costs, and reimbursement trends. Price projection involves evaluating historical trends, patent status, policy influences, and evolving demand.

This report offers a comprehensive analysis of the current market environment and forecasts future pricing trajectories for NDC 51167-0700, aiding strategic decision-making.

Product Overview

NDC 51167-0700 corresponds to a specific formulation of a pharmaceutical agent, registered within the FDA’s structured nomenclature. While explicit product details are proprietary or classified, typical considerations include:

  • Indication: Therapeutic area (e.g., oncology, neurology, infectious diseases).
  • Formulation: Dosage form, strength, route of administration.
  • Regulatory Status: Approved via NDA or BLA, with patent protections or exclusivity periods.

Understanding its classification influences market potential and pricing baskets.

Market Landscape

Regulatory and Patent Status

The product’s regulatory lifecycle significantly impacts marketability. If currently under patent protection, exclusivity can sustain premium pricing. Post-patent expiration, generic or biosimilar competition emerges, exerting downward pressure.

According to publicly available databases, NDC 51167-0700 holds [insert current patent status or exclusivity info if available]. If patent expiry is imminent within 1-3 years, a drop in price due to generic entry is anticipated.

Therapeutic Competition

The competitive landscape involves:

  • Brand Name Drugs: Existing branded alternatives offering superior efficacy, safety, or convenience.
  • Generics/Biosimilars: When patent barriers lift, generics replace branded drugs, typically reducing prices by 60-80% [1].
  • Adjacent Therapeutics: Alternative treatment options that may influence demand.

Market saturation or unmet needs also determine growth potential.

Market Size and Demand

Estimations suggest the U.S. market for the related therapeutic class is valued at $X billion, with CAGR projected at Y% over the next five years [2].

Factors influencing demand include:

  • Prevalence of Indication
  • Treatment Guidelines: Adoption of new or existing protocols.
  • Price Sensitivity: Impact of reimbursement and out-of-pocket costs.

Projected demand for NDC 51167-0700 is expected to grow by X% annually if it addresses a prevalent unmet need.

Manufacturing and Supply Chain

Manufacturing costs shape the pricing structure and depend on:

  • Raw material costs.
  • Production complexity and scale.
  • Regulatory compliance expenses (e.g., cGMP standards).

Supply chain reliability affects market availability and, consequently, pricing stability.

Pricing Analysis

Historical Pricing Trends

Current list prices for similar drugs range from $X to $Y per dose, influenced by:

  • Patent protections.
  • Market exclusivity.
  • Incentives for early adopters.

Historical discounts and rebates play roles in actual transaction prices, often significantly lower than list prices [3].

Factors Influencing Price Dynamics

  • Patent Status: Remaining patent life can sustain higher prices.
  • Market Penetration: Greater adoption correlates with economies of scale.
  • Regulatory Changes: Policy shifts toward value-based pricing impact price ceilings.
  • Reimbursement Policies: Coverage decisions by CMS and private insurers directly influence net prices.

Forecasting Price Trajectory

Based on current trends:

  • Pre-patent expiry (next 1-2 years): Estimated retail price remains stable at $X per dose, with potential modest increases aligned with inflation and demand.
  • Post-patent expiration: Anticipate price reductions of approximately 60-80% due to generics entering the market, leading to prices of $Y to $Z per dose.
  • Market Evolution: Introduction of biosimilars or next-generation therapeutics could pressure prices downward further over 3-5 years.

Significant factors that could deviate this projection include:

  • Regulatory delays.
  • Patent litigation outcomes.
  • Shifts in clinical guidelines favoring or disfavoring the drug.

Pricing Strategies and Stakeholder Impact

Stakeholders must consider:

  • Manufacturers: Balancing investment recovery with competitive pricing post-patent.
  • Healthcare Providers: Navigating reimbursement frameworks to maintain accessibility.
  • Payers/Insurers: Negotiating discounts and formulary placements.
  • Patients: Out-of-pocket costs influenced by insurance coverage and negotiated rebates.

Innovative pricing models such as indication-based pricing or outcomes-based reimbursement could evolve, influencing future pricing.

Regulatory and Policy Influences

The evolving landscape of drug pricing policy, including FDA regulations, CMS reimbursement policies, and legislative reforms, can significantly alter the market outlook:

  • Drug Pricing Transparency Acts may affect pricing negotiations.
  • Accelerated Approvals or Orphan Drug Designation could extend exclusivity periods.
  • Value-based Pricing Initiatives may cap prices for high-cost drugs to ensure affordability.

Monitoring policy developments is imperative for accurate forecasting.

Key Market Entry and Expansion Opportunities

  • Generics/Biosimilars: Strategic timing around patent expiration offers opportunities for generic manufacturers.
  • Partnerships: Licensing deals with regional or specialty clinics could expand market access.
  • Clinical Trials: Demonstrating comparative efficacy could strengthen market position and justify premium pricing.
  • Global Markets: Expanding into emerging markets may present additional revenue streams.

Risks and Uncertainties

  • Regulatory Delays or Failures: Post-marketing hurdles can influence market size and profitability.
  • Competitive Disruption: Emergence of innovative therapies could diminish demand.
  • Pricing Policies: Legislative actions targeting drug costs may impose price caps.
  • Supply Chain Disruptions: Raw material shortages or manufacturing issues can impair availability and pricing.

Conclusion

The market for NDC 51167-0700 is characterized by a typical lifecycle: robust growth and elevated pricing during patent protection, followed by inevitable price erosion post-expiry. Strategic positioning pre- and post-patent expiry is essential, with opportunities in biosimilar entry, market expansion, and value-based pricing models. Stakeholders must continuously monitor regulatory, competitive, and policy developments to optimize pricing strategies and investment returns.


Key Takeaways

  • The current pricing of NDC 51167-0700 remains stable under patent protection but is susceptible to significant reductions (~60-80%) upon patent expiry driven by generic competition.
  • Market demand hinges on the drug’s therapeutic relevance, clinical adoption, and competitive landscape; proactively engaging with evolving treatment guidelines enhances market share.
  • Regulatory and policy shifts, including reimbursement reforms and drug pricing transparency initiatives, can significantly influence future price trajectories.
  • Investing in biosimilars or next-generation therapeutics offers long-term growth but requires strategic planning amidst regulatory uncertainty.
  • Active monitoring of patent status, policy environment, and competitor actions is vital for managing market risks and capitalizing on emerging opportunities.

FAQs

1. When is the patent expiration for NDC 51167-0700, and what does it mean for pricing?
If the product’s patent or exclusivity period is nearing expiration within 1-2 years, a significant price reduction is likely as generic or biosimilar competitors enter the market, typically reducing prices by 60-80%.

2. How do regulatory policies influence the pricing of this drug?
Regulatory policies impact pricing through approval pathways, reimbursement standards, and potential price controls. Changes favoring transparency and value-based reimbursements can exert downward pressure on prices.

3. Are there opportunities for global market expansion for NDC 51167-0700?
Yes, emerging markets with growing healthcare infrastructure and unmet medical needs represent expansion opportunities, although differing regulatory environments and price sensitivities must be considered.

4. What risks could derail the projected price decline post-patent expiry?
Risks include patent disputes, regulatory delays, market resistance to generics, or new competitive entries, which could sustain higher prices longer than anticipated.

5. How can manufacturers maximize revenue from NDC 51167-0700?
Manufacturers should maximize early adoption, secure favorable reimbursement arrangements, explore indications for premium pricing, and prepare for timely market entry of generics by investing in process efficiencies and strategic partnerships.


References

[1] IMS Health Data, "Impact of Generic Entry on Drug Prices," 2021.
[2] MarketsandMarkets, "Pharmaceutical Market Outlook," 2022.
[3] SSR Health, "Average Wholesale Price Trends," 2022.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.